logo
  

Allscripts Loss In Line, Revenue Misses; Stock Down 5% On Weak Guidance

Allscripts Healthcare Solutions Inc (MDRX), an electronic health records company, on Thursday reported fourth-quarter net loss of $2.2 million or $0.01 per share compared with a loss of $20.6 million or $0.12 per share last year.

Excluding items, adjusted earnings for the quarter were $0.09 per share compared with $0.08 per share a year ago.

Analysts polled by Thomson Reuters estimated earnings of $0.09 per share for the quarter. Analysts' estimates typically exclude special items.

Revenues for the quarter were $340.9 million compared with $351 million in the prior year. Adjusted revenues totaled $343.2 million compared with $354 million in the prior year.

Analysts estimated revenues of $357.5 million for the quarter.

Gross margin for the quarter rose to 43.9 percent from 44.4 percent last year, and operating expenses fell 19 percent, the company said.

For the full year 2015, the company expects earnings of $0.42 to $0.50 per share on revenues of $1.43 billion to $1.46 billion. Analysts expect earnings of $0.47 per share on revenues of $1.48 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT